Partner-equity, six regions, nine owners — so the programme covered the sixteen locations whose partners bought in, not the ones we would have picked. 24 → 42 locations. Same-store new patients 34 → 41 a month over thirty-four months; all-in 34 → 37, because eighteen of the forty-two were immature at discharge. Cost per new patient improved same-store and rose all-in, and collections per new patient fell.

T he group came to us at 24 locations and stalled: 34 new patients per location per month, against an industry average of 39. What follows took thirty-four months, and the headline movement is a 21% same-store gain — real, and roughly what this work produces when it goes well. It is not a doubling. Groups that double new-patient volume in a year exist and we have seen a handful; in every case the constraint that broke was chair capacity, not marketing, and the practice had the operatories to absorb it. This one did not, and pretending otherwise would misdescribe both the engagement and the trade. They finished at 42 locations, and eighteen of those forty-two were opened during the engagement — twelve of them de novo, six in towns where the brand had never traded. Nor was the same work done everywhere, and the reason is ownership rather than clinical judgement. This is not a corporate chain. It is partner-equity: nine partners holding equity across six regions, each region carrying its own P&L. There is no head office that can order a media budget into a region. There is only a case you make to nine people who each own their own outcome, and who each get to say no. So the sixteen of forty-two locations in the acquisition programme is not a scope we set. It is an adoption number — three regions bought in at the start, covering sixteen locations, and the others watched. Reporting that as though we had chosen the sites would flatter us and misdescribe the engagement. Two of the regions that declined were right to decline: several of their sites were already running at or near chair capacity, where additional spend buys demand the schedule cannot absorb and the only result is a worse cost per patient. What the holding company could mandate, it did — intake instrumentation and reporting went company-wide, because measurement is a shared service on a shared cost line while media is regional money. That split is the governance story in one sentence, and it decided more about this engagement than any campaign did. Two markets ran as tests for eleven weeks before anything was rolled outward. So the figures below carry two different populations, and mixing them would be the easiest way to overstate this engagement. That segmentation matters more than anything else on this page, so it is stated first rather than buried: every blended per-location figure below is dragged down by immature sites, and that drag is mechanical, not a failure. National Vision, which files its ramp publicly, targets a new store at 55% of year-five sales in its first full year and reaches profitability in year two. A group that adds eighteen locations in thirty-four months and shows no blended decline is describing something that does not happen. How far underwater the twelve de novo sites finish is not something this record will state, because we do not know it and we have not seen a number worth printing from anyone who claims to. It depends on things that vary far more than the average does: catchment density, the operator running the site, whether the region carried any brand recognition before the doors opened, how consolidated the local competition already was, and what media cost in that market in the month it launched. The filed National Vision curve is the only external anchor we will put near it, and that describes a chain of optical stores rather than a dental practice — it bounds the shape of the ramp, not its depth. Anyone who quotes a single de novo payback figure across markets is quoting an average that no individual site will actually experience. Their hub domain was outranking its own location pages on the queries that mattered — we never put a percentage on that, because no honest one exists. The front-desk leak we did measure. Roughly two qualified new-patient calls per location per month died unbooked; 2 × 24 locations × 12 months = 576 patients a year, valued at the $887 MEPS mean annual dental expenditure per person with a dental expense. About $511,000, and the arithmetic is the whole claim. What did not improve: cost per new patient rose all-in, $268 to $292. Same-store it fell only to $235. Nor did collections per new patient across the first twelve months, which fell 6.6% from $1,040 to $971 — the volume that arrived was less established and carried more payer discount than the base it joined, and that is the standing cost of buying growth rather than the exception to it. Both are true and the gap is the story — twelve de novo markets with no brand equity cost more to enter than an established catchment does to defend, and they were entered across thirty-four months of rising media prices. Case acceptance improved less than the same-store new-patient gain would suggest — 44% to 47%, not the 53%-plus a 21% volume gain might imply — and for a reason worth naming: a larger share of first visits were unestablished patients, and unestablished patients accept less treatment. Volume and acceptance pull against each other, and any record showing both rising in lockstep is not reporting from a practice management system. Production variance closed to 4.2× among the mature pods and only to 5.2× across all forty-two, because the new sites are now the outliers the mature ones used to be. The market mattered too. This was not an open catchment: it is a Sun Belt corridor with active DSO and PE-backed consolidation, and holding position there costs more than the same work would cost in a market without sophisticated competitors.

We spent six weeks inside their ops. We rebuilt the location template, instrumented intake to the call rather than the form, and mapped paid pressure to local demand curves market by market. We didn't change their brand. We didn't have to. The finding that paid for the engagement was dispersion: a 7.1× production spread between pods running identical staffing — the same pathology MGMA measures across 141 multispecialty groups, where total medical revenue per FTE physician runs from $250K to $1.8M at comparable staffing levels.

By month 30 new patients per location had reached 41 a month — above the 39 industry average on Henry Schein One's scale, still short of the 45 where its strong band begins, and a long way short of the 82 that marks the top decile. Cost per new patient is their own instrumented number, their spend over their own counted new patients: general dentistry publishes no acquisition-cost benchmark at all, and we do not pretend otherwise. It read $268 at intake and $235 at exit same-store, against $292 all-in. The banker was engaged in month 31.